{"hq_id":"hq-p-pet-000079","name":"Veterinary NSAIDs (Carprofen, Meloxicam — Therapeutic Use, Overdose, and Off-Label Risk in Cats)","category":{"primary":"pet","secondary":"veterinary_medication","tags":["carprofen","meloxicam","NSAID","rimadyl","metacam","veterinary medication","GI ulceration","renal failure","cat","dog","off-label"]},"product_tier":"PET","overall_risk_level":"moderate_to_high","description":"Veterinary non-steroidal anti-inflammatory drugs (NSAIDs) — primarily carprofen (Rimadyl, Novox) and meloxicam (Metacam, Loxicom) — are first-line pharmacotherapy for canine osteoarthritis, post-surgical pain, and chronic inflammatory conditions. Both are COX-2-preferential inhibitors with FDA-CVM approval for dogs; meloxicam has a one-time-injectable feline approval (post-operative only). Therapeutic-dose risk in dogs centers on GI ulceration (5-10% incidence on chronic dosing per FDA-CVM ADE database), idiosyncratic hepatotoxicity (carprofen — Labrador over-representation), and renal papillary necrosis (especially in dehydrated, hypovolemic, or geriatric dogs). The dominant safety signal in pet households is OFF-LABEL CHRONIC USE IN CATS — cats are markedly more sensitive to NSAIDs than dogs because they lack hepatic glucuronidation capacity for these substrates. The FDA issued a 2010 safety advisory after multiple feline deaths from off-label meloxicam dispensing; the boxed warning explicitly prohibits repeated/chronic administration. ASPCA APCC ranks NSAID ingestion (combined human + veterinary) in the top 5 pet poison-call categories, with cats accounting for disproportionate mortality. Owner-driven dose mistakes (giving two doses, sharing across multi-dog households, dosing by guess rather than weight) are the second largest exposure driver.","synthesis":{"derived_risk_level":"low","synthesis_confidence":0.5,"synthesis_method":"compound_composition","context_used":"human_infant","context_source":"available_priority","exposure_modifier":1.15,"vulnerability_escalated":false,"escalation_reason":null,"compounds_resolved":2,"compounds_total":2,"synthesis_date":"2026-05-09","synthesis_version":"1.2.0","methodology_note":"exposure_modifier and adjusted_magnitude are computed from ALETHEIA-calibrated heuristics (route × duration × frequency multipliers, clamped to [0.5, 1.4]). Multipliers are directionally informed by EPA Exposure Factors Handbook (2011) and CalEPA OEHHA but are not regulatory consensus. See /api/methodology for full disclosure."},"hazard_summary":{"sensitive_populations":"cats (UGT1A6-deficient, off-label use), geriatric dogs, dogs with renal/hepatic compromise, dehydrated animals","overall_risk":"moderate_to_high","primary_concerns":["Off-label chronic meloxicam in cats — acute renal failure, FDA boxed warning","Carprofen idiosyncratic hepatotoxicity (Labrador over-representation)","GI ulceration on chronic dosing (5-10% incidence per FDA-CVM ADE database)","Renal papillary necrosis in dehydrated/hypovolemic/geriatric dogs","Owner double-dosing or dosing across multi-dog households by weight error"],"exposure_routes":"Oral ingestion (therapeutic dose, accidental double-dose, multi-pet cross-dosing, off-label feline dispensing)"},"exposure":{"routes":["oral"],"contact_types":["oral_direct","oral_accidental"],"users":["pet_dog","pet_cat"],"duration":"chronic","frequency":"daily","scenarios":["Therapeutic chronic dosing for canine osteoarthritis (months to years)","Owner gives an extra dose because the pet seemed in pain — double-dose toxicity","Off-label chronic meloxicam dispensing in cats (FDA boxed-warning violation)","Multi-dog household — wrong-weight dose given to the smaller dog","Dehydrated/hypovolemic dog continues NSAID therapy through illness — renal injury"],"notes":"Carprofen FDA-CVM NADA 141-053 (Pfizer 1997). Meloxicam FDA-CVM NADA 141-219 (Boehringer 2003) — feline injectable label restricted to one-time post-op dose. FDA 2010 safety alert: repeated meloxicam in cats causes acute renal failure and death. Cats deficient in UGT1A6 glucuronidation pathway — half-life of meloxicam in cats ~15 hours vs 12-24 hours in dogs but with markedly lower clearance margin. Carprofen idiosyncratic hepatotoxicity: ~1 in 5,000 dogs; pre-treatment ALT/AST and follow-up at 2-4 weeks recommended (AAHA 2022 chronic-pain guidelines)."},"consumer_guidance":{"usage_warning":"NEVER give carprofen or meloxicam to a cat without explicit, current veterinary supervision — chronic feline dosing is FDA-prohibited and causes death from acute renal failure. Dose strictly by weight, not visual estimate. Do not double-dose if a dose is missed — skip and resume at the next scheduled time. Discontinue and contact the veterinarian if vomiting, melena, lethargy, anorexia, increased thirst/urination, or jaundice develops. Maintain hydration during NSAID therapy; discontinue temporarily during diarrhea/vomiting illness. Baseline and 2-4 week ALT/AST/BUN/creatinine monitoring recommended for chronic carprofen therapy.","safer_alternatives":["Galliprant (grapiprant) — EP4-receptor antagonist, lower GI/renal risk profile vs COX inhibitors (dogs only)","Solensia (frunevetmab) for feline chronic pain — anti-NGF monoclonal antibody, FDA-approved 2022","Librela (bedinvetmab) for canine chronic pain — anti-NGF mAb, FDA-approved 2023","Adjunctive non-pharmacologic: weight management, physical rehabilitation, joint supplements, acupuncture","Tramadol or gabapentin for acute pain where NSAID contraindicated (cats, renal disease)"]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"FDA Center for Veterinary Medicine (CVM)","citation":"21 U.S.C. 360b; 21 CFR Parts 514, 530, 558","requirements":"New animal drugs require FDA-CVM approval (NADA/ANADA). Adverse Drug Experience (ADE) reporting under 21 CFR 514.80. Extralabel use governed by AMDUCA (1994) and 21 CFR 530.","compliance_status":null,"effective_date":null,"enforcing_agency":"FDA-CVM","penalties":null,"source_ref":null},{"jurisdiction":"USA","regulation":"AVMA Animal Poison Control reporting","citation":"Voluntary; ASPCA APCC + Pet Poison Helpline data referenced by FDA-CVM","requirements":"Veterinary professionals report adverse drug events to FDA-CVM Form 1932a; consumers report via 1-888-FDA-VETS or APCC.","compliance_status":null,"effective_date":null,"enforcing_agency":"AVMA / FDA-CVM","penalties":null,"source_ref":null},{"jurisdiction":"EU","regulation":"Veterinary Medicinal Products Regulation (EU) 2019/6","citation":"Regulation (EU) 2019/6 (effective 28 January 2022)","requirements":"Centralised authorisation for veterinary medicines via EMA. Pharmacovigilance reporting mandatory for marketing authorisation holders.","compliance_status":null,"effective_date":"2022-01-28","enforcing_agency":"EMA / national CAs","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":false,"disposal_guidance":"Unused/expired NSAIDs: return to veterinary clinic or DEA take-back location. Do not flush. Do not place in regular trash where pets/wildlife may access.","hazardous_waste":false,"expected_lifespan":"tablet 24-month shelf life; oral suspension 6 months once opened"},"formulation":{"form":"varies","key_ingredients":[],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-org-000186","compound_name":null,"role":"active_ingredient","typical_concentration":"carprofen 25-100 mg tablets; therapeutic 4.4 mg/kg/day in dogs"},{"hq_id":"hq-c-org-000185","compound_name":null,"role":"active_ingredient","typical_concentration":"meloxicam 1.5 mg/mL oral suspension; therapeutic 0.1 mg/kg dog Day 1, 0.1 mg/kg/day maintenance"}],"identifiers":{"common_names":["veterinary nsaids (carprofen, meloxicam — therapeutic use, overdose, and off-label risk in cats)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[],"brand_examples_disclaimer":null,"sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-05-08"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-05-08","timestamp":"2026-06-11T20:57:54.371Z"},"_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer"}